Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. AUROBINDO PHARMA LIMITED (D.N.J. 2014)

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. AUROBINDO PHARMA LIMITED (D.N.J. 2014)

Docket		Date Filed	2014-05-23
Court	District Court, D. New Jersey	Date Terminated	2018-02-07
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Karen M. Williams
Patents	8,017,615; 8,580,796; 8,642,760
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. AUROBINDO PHARMA LIMITED (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-05-23				External link to document

Otsuka Pharmaceutical v. Aurobindo Pharma: Litigation Summary and Patent Analysis

Last updated: October 9, 2026

Otsuka Pharmaceutical Co., Ltd. v. Aurobindo Pharma Limited, No. 1:14-cv-03306, was an ANDA patent action involving generic aripiprazole tablets, the active ingredient in Abilify. Otsuka filed the case after Aurobindo notified Otsuka of a Paragraph IV certification challenging patents listed for the product. The dispute was resolved without a reported merits decision, leaving no judicial finding that the challenged patents were valid, infringed, or enforceable.[1]

What drug and ANDA were involved in Otsuka v. Aurobindo?

The case concerned aripiprazole tablets, marketed by Otsuka as Abilify.

Item	Case information
Brand	Abilify
Active ingredient	Aripiprazole
Dosage form	Immediate-release oral tablets
Originator	Otsuka Pharmaceutical Co., Ltd.
Generic applicant	Aurobindo Pharma Limited
Regulatory pathway	ANDA
Case number	1:14-cv-03306
Filing year	2014
Litigation type	Hatch-Waxman patent litigation
Outcome	Resolved without a reported merits judgment

Abilify was approved by the FDA for schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder. The product’s commercial protection included the original compound patent, method-of-use protection, formulation and dosage-form patents, and FDA regulatory exclusivity.[2]

Aurobindo’s ANDA sought approval to market generic aripiprazole before the expiration of at least one patent listed in the FDA’s Orange Book. The Paragraph IV certification created the statutory basis for Otsuka’s infringement action under the Hatch-Waxman Act.

What patents protected Abilify in the Otsuka-Aurobindo litigation?

The core Abilify patent estate included the original aripiprazole compound patent and later patents covering clinical uses, dosage regimens, and pharmaceutical formulations.

Original aripiprazole compound patent

U.S. Patent No. 5,006,528 covered aripiprazole as a chemical compound. The patent was assigned to Otsuka and expired in 2015, subject to any applicable patent-term adjustment or extension.[3]

The compound patent provided the broadest protection but was no longer sufficient by itself to block generic entry in the 2014 litigation because its expiration was approaching. Otsuka therefore relied on later-listed patents to extend protection for specific uses and product characteristics.

Method-of-use and dosage patents

Otsuka also held patents directed to the use of aripiprazole in treating psychiatric disorders and to specified dosing regimens. These patents could support infringement claims even after the underlying compound patent had expired, but their practical value depended on the scope of the ANDA labeling and the applicant’s proposed prescribing information.

A method-of-use patent is generally weaker against a generic applicant when the applicant can obtain approval with a section of the branded label removed through a “skinny label.” If the generic label omits the patented indication, the brand company must prove that the proposed label still induces infringement or that the applicant’s conduct will otherwise lead to infringement.

Formulation and tablet patents

Later Abilify patents covered tablet composition, dosage forms, manufacturing characteristics, or other product attributes. Such patents generally presented a more direct barrier to approval because they could cover the generic product itself rather than only a particular clinical use.

The commercial strength of a formulation patent depends on four factors:

1. The number of claim limitations required for infringement.
2. Whether the ANDA discloses the relevant excipients, ratios, particle characteristics, or manufacturing process.
3. Whether the generic applicant can redesign the product without losing bioequivalence.
4. Whether the patent remains listed and enforceable when FDA approval becomes effective.

The public record for No. 1:14-cv-03306 does not contain a reported claim-construction ruling or trial decision establishing the precise scope of the patents asserted against Aurobindo.[1]

How did the Paragraph IV challenge trigger the lawsuit?

Under the Hatch-Waxman framework, an ANDA applicant can certify that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. That certification is commonly called a Paragraph IV certification.[4]

Otsuka’s receipt of Aurobindo’s Paragraph IV notice gave Otsuka 45 days to file an infringement action. The filing of the action triggered a statutory 30-month stay of FDA approval, unless the court issued an earlier decision or the litigation was otherwise resolved.[4]

The litigation therefore had two immediate effects:

• It delayed FDA approval of Aurobindo’s ANDA during the statutory stay.
• It shifted the commercial launch decision from FDA review alone to a patent-risk assessment involving Otsuka’s listed patents.

A Paragraph IV filing is not a judicial determination that a patent is invalid or that a generic product is noninfringing. It is the applicant’s legal position, which the brand owner can challenge in federal court.

What was the litigation outcome?

The case did not produce a reported opinion resolving patent validity, infringement, or enforceability. The action was resolved through docket activity rather than a published trial judgment.[1]

The absence of a merits ruling is commercially important. It means the case does not establish binding precedent on:

• The validity of Otsuka’s aripiprazole patents.
• The construction of disputed patent claims.
• Whether Aurobindo’s proposed tablets infringed.
• Whether any patent was unenforceable because of inequitable conduct.
• Whether a particular formulation limitation was necessary for infringement.

The disposition should therefore be characterized as a case-specific resolution, not as a judicial confirmation of Otsuka’s patent estate.

Did Otsuka and Aurobindo enter a settlement agreement?

The public docket reflects resolution of the action, but the commercially material terms of any agreement were not publicly disclosed in a reported opinion.

In Hatch-Waxman cases, settlement terms commonly address:

• The date on which the generic applicant may launch.
• Whether the launch is authorized or contingent.
• Restrictions on marketing, manufacturing, or distribution.
• Treatment of later patent challenges.
• Release of infringement claims.
• Potential supply, licensing, or commercialization rights.

The docket alone does not establish a specific authorized-launch date, payment provision, license scope, or “first-filer” arrangement for Aurobindo. Those terms should not be inferred from dismissal or termination entries.

What was the Orange Book status of Abilify?

The FDA Orange Book listed multiple patents for Abilify over time. The listing status changed as patents expired, delisted, or reached the end of their regulatory relevance.

Patent category	Commercial role
Compound patent	Broad protection for aripiprazole
Method-of-use patent	Protection for specified psychiatric indications
Dosage-regimen patent	Protection for dose, schedule, or treatment method
Formulation patent	Protection for tablet composition or product characteristics
Regulatory exclusivity	Separate from patent rights and controlled by FDA approval dates

The Orange Book does not decide whether a listed patent is valid or infringed. It records patents submitted by the NDA holder and accepted for listing under FDA rules. A listed patent can later be invalidated, narrowed, delisted, or rendered commercially ineffective by a noninfringing generic design.[5]

Abilify’s original compound protection expired before or around the first wave of generic entry. Generic aripiprazole subsequently entered the U.S. market, confirming that the product did not retain perpetual market protection from its later patents.

When did Abilify lose exclusivity?

Abilify lost its principal compound-based exclusivity in 2015 when U.S. Patent No. 5,006,528 expired, subject to statutory patent-term adjustments and extensions.[3]

The practical exclusivity timeline was more complex because Otsuka’s later patents covered uses and product characteristics.

Period	Protection event
1980s-1990s	Aripiprazole development and patent filings
2002	FDA approval of Abilify tablets
2011-2014	Later formulation and use patents supported additional patent litigation
2014	Otsuka sued Aurobindo after the Paragraph IV challenge
2015	Original compound patent protection ended
2015 onward	Generic aripiprazole entered in stages, subject to remaining patents and settlements

FDA regulatory exclusivity and patent exclusivity are separate. FDA exclusivity can restrict approval of competing applications, while patents can block commercial launch through infringement liability. Neither form of protection automatically extends the other.[6]

What generic entry risks did Aurobindo present?

Aurobindo presented a standard early-entry challenge to Otsuka’s aripiprazole franchise.

Product-level risk

If Aurobindo’s ANDA product fell within the claims of a formulation patent, Otsuka could seek an injunction or damages. Product claims are generally more difficult to avoid through label changes because they attach to the tablet itself.

Label-level risk

If the dispute centered on patented indications, Aurobindo could potentially use a skinny-label strategy. That approach would remove patented indications from the proposed label while retaining unpatented indications, assuming the resulting label satisfied FDA requirements.

Timing risk

The 30-month stay delayed approval but did not guarantee Otsuka a final injunction. Once the statutory stay expired, FDA approval could proceed unless a court entered an injunction or the parties’ settlement imposed a different restriction.

Commercial erosion risk

Aripiprazole was a high-volume branded antipsychotic. Generic entry exposed Otsuka to rapid price erosion and prescription switching. In antipsychotics, substitution can occur quickly after generic approval, although branded prescriptions may persist because of physician preference, payer controls, patient stability concerns, and rebate arrangements.

How strong was Otsuka’s patent estate?

Otsuka’s estate was strong during the period when the compound patent and later patents overlapped. Its strength declined as the compound patent expired and generic applicants attacked the remaining patents.

Strength factor	Assessment
Broad chemical coverage	Strong historically, but expiration was imminent in 2014
Remaining patent term	Depended on later patents and patent-term adjustments
Formulation protection	Potentially meaningful if the claims covered unavoidable product characteristics
Method-of-use protection	More vulnerable to skinny-label strategies
Litigation leverage	High enough to delay approval, but not supported by a reported merits victory in this case
Long-term barrier	Limited once generic aripiprazole entered the market

The case did not produce a judicial validation of the estate. Its principal value to Otsuka was procedural and strategic: it invoked the Hatch-Waxman stay, preserved negotiation leverage, and delayed Aurobindo’s regulatory pathway while the parties resolved the dispute.

Did the case create biosimilar risk?

No. Biosimilar risk was not relevant because aripiprazole is a small-molecule drug, not a biologic.

Aurobindo pursued an ANDA, not a biosimilar application under the Public Health Service Act. The relevant competitive threats were generic tablets, Paragraph IV certifications, formulation design-arounds, and potential authorized-generic strategies.

What was the revenue exposure from Aurobindo’s challenge?

Abilify generated multibillion-dollar annual sales before generic entry. Otsuka and its commercialization partner Bristol-Myers Squibb reported substantial Abilify revenue before the product lost exclusivity.[7]

The revenue exposure had three layers:

1. Direct loss of branded tablet sales after generic approval.
2. Price compression from pharmacy substitution and payer negotiations.
3. Spillover effects on related aripiprazole products, including long-acting injectable formulations, although tablet litigation did not automatically cover Abilify Maintena.

The financial impact depended on the launch date, number of generic competitors, market share captured by Aurobindo, and whether a settlement permitted an authorized generic or delayed entry.

What is the competitive significance of the case?

The case was part of the broader first-wave generic challenge to Abilify. Aurobindo was one of several generic manufacturers seeking access to the aripiprazole market as the compound patent approached expiration.

The competitive landscape included:

• Generic manufacturers filing ANDAs for aripiprazole tablets.
• Otsuka defending later patents.
• Bristol-Myers Squibb managing the commercial transition before the end of its Abilify relationship.
• FDA review of multiple ANDAs and patent certifications.
• Pharmacy and payer substitution after generic approval.

The case’s principal competitive effect was timing. It did not permanently prevent generic aripiprazole entry. It formed part of the litigation and settlement process that determined when Aurobindo could compete.

Key Takeaways

• Otsuka v. Aurobindo involved an ANDA for generic aripiprazole tablets.
• The case was triggered by a Paragraph IV challenge to Orange Book-listed Abilify patents.
• Otsuka’s original aripiprazole compound patent expired in 2015.
• Later method-of-use and formulation patents provided additional litigation leverage.
• The case ended without a reported merits ruling on validity, infringement, or enforceability.
• Public docket materials do not establish the complete commercial terms of the resolution.
• The dispute created generic-entry delay risk, not biosimilar risk.
• Abilify’s long-term exclusivity ended as generic aripiprazole entered the U.S. market.

FAQs About Otsuka Pharmaceutical v. Aurobindo Pharma

Was Aurobindo the first generic company to challenge Abilify?

The case record establishes Aurobindo as a Paragraph IV challenger, but the docket does not by itself establish whether Aurobindo was the first applicant to file a substantially complete ANDA for the relevant strength and formulation.

Did Otsuka win the Abilify patent case?

No reported merits judgment establishes that Otsuka won on patent validity or infringement. The action was resolved without a published trial decision.

Did Aurobindo launch generic aripiprazole?

Aurobindo was among the companies pursuing generic aripiprazole approval. A case-specific launch date cannot be inferred solely from the civil docket or the filing of the Paragraph IV litigation.

Did the litigation involve Abilify Maintena?

The action concerned oral aripiprazole tablets, not a biosimilar or a biologic product. Abilify Maintena is a separate long-acting injectable product with a distinct regulatory and patent profile.

What patent strategy did Otsuka use against generic aripiprazole?

Otsuka combined the expiring compound patent with later patents directed to methods of treatment, dosing, and product or formulation characteristics. That layered strategy delayed generic approval negotiations but did not prevent eventual generic entry.

References

1. U.S. District Court for the Southern District of New York. (2014). Otsuka Pharmaceutical Co., Ltd. v. Aurobindo Pharma Limited, No. 1:14-cv-03306. PACER/CourtListener docket record.
2. U.S. Food and Drug Administration. (2002). Abilify (aripiprazole) prescribing information.
3. United States Patent and Trademark Office. (1988). U.S. Patent No. 5,006,528, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone.
4. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Food and Drug Administration. (2017). Abbreviated new drug application regulations and patent certifications.
7. Bristol-Myers Squibb Company. (2014). Annual report for the fiscal year ended December 31, 2014.